Previous Close | 26.67 |
Open | 26.71 |
Bid | 29.80 x 200 |
Ask | 30.12 x 400 |
Day's Range | 26.39 - 30.09 |
52 Week Range | 6.76 - 35.38 |
Volume | |
Avg. Volume | 1,907,184 |
Market Cap | 2.801B |
Beta (5Y Monthly) | 0.48 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.36 |
Earnings Date | Nov 12, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 39.88 |
CAMBRIDGE, Mass., November 15, 2024--Scholar Rock (NASDAQ: SRRK; the "Company"), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy, cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that the company granted inducement equity awards covering an aggregate of 100,500 shares of its common stock to four newly hired employees, consisting of inducement stock options to p
Scholar Rock Holding Corp (SRRK) reports significant progress in its SAPPHIRE study and financial growth, setting the stage for future market expansion.